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Altered expression of transforming growth factor-13s in chronic renal
rejection. We examined the altered expression of transforming growth
factor-J3s in chronic renal rejection in humans, including transforming
growth factor beta-i (TGF-j3i), TGF-132, TGF-f33 and their receptors,
transforming growth factor beta receptor type I (TI3R-I) and TJ3R-II.
Using Northern blot analysis and immunohistochemistry, 10 specimens of
chronically rejected and 8 normal kidney samples were analyzed. By
Northern blot analysis the expression of mRNA encoding TGF-f3i,
TGF-132, TGF-j33 (P < 0.02),TR-I and TI3R-II (P < 0.02) was decreased
in chronically rejected renal cortex samples, compared to normal controls.
Immunohistochemical analysis of the normal renal cortex showed strong
immunostaining for TGF-/3i and TGF-133, and mild immunostaining for
TGF-p2 in the proximal and distal tubulointerstitium, but no signal for any
of the TGF-/3 isoforms in the glomeruli or in the cortical vessels. In sharp
contrast, the glomeruli and the cortical vessels of the rejected kidney
specimens exhibited strong immunostaining for TGF-/31 and TGF-/33,
whereas the tubules revealed a decrease in immunoreactivity. T/3R1 and
TJ3RII immunostaining showed similar changes as observed with TGF-/31
and TGF-/33 antibodies. There was a concomitant increase in B-cell
accumulation in the glomeruli, while T-cells and macrophages were
diffusely abundant in the rejected samples. Since TGF-13s are potent
inducers of extracellular matrix proteins and have been shown to be
involved in fibrotic disease, the increase in TGF-131 and TGF-133 immu-
noreactivity in the glomeruli suggests that there is a redistribution in
TGF-13 expression in chronic renal allograft rejection. Together with
changes affected by B-cell mediated immunity, the above alterations might
contribute to the histopathological changes that occur in this disorder,
such as intimal fibrosis, arteriosclerosis and glomerular and tubular
sclerosis.
Chronic rejection is the most common cause of graft loss in
renal transplantation. Despite this fact, research has mainly
focused on the prevention of acute rejection with the development
of powerful immunosuppressants. To date, no effective treatment
has been developed for the irreversible damage associated with
chronic rejection. The most characteristic histopathological fea-
tures of chronic rejection in renal allografts are intimal fibrosis
mainly in the cortical arteries, glomerular ischemic simplification,
interstitial fibrosis and tubular atrophy.
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T cell mediated immunity plays a critical role in allograft
rejection [1]. A variety of interactions have been implicated in the
rejection process, including cytokines such as IL-i, IL-2, trans-
forming growth factor beta-I (TGF-/31), TGF-32 and TGF-133 [2,
3]. The initial targets of rejection appear to be the graft endothe-
hal structures. Interstitial mononuclear cells (lymphocytes, mac-
rophages, plasma cells, eosinophil cells) infiltrate the rejected
graft and serve as histological indicators of chronic cell-mediated
rejection.
TGF-/31, TGF-/32 and TGF-133 belong to a superfamily of
multifunctional homologous polypetide growth factors, which act
through pleiotropic effects in various cell types [4, 5]. They play a
major role in the regulation of extracellular matrix formation and
fibrosis, arteriosclerosis and angiogenesis, immunosuppression,
carcinogenesis, inflammation, tissue repair and also in normal
differentiation and growth [6—12]. TGF-pl, TGF-p2 and TGF-/33
are the mammalian isoforms of TGF-f3. In addition cDNA clones
have also been isolated for TGF-f34 from chicken [13], and
TGF-/35 from frog [14], but these proteins have not been identi-
fied in mammalian cells.
TGF-j3s bind to specific cell surface binding proteins with high
affinity in many different cell types. Two receptors involved in
signal transduction have been identified, a 53 kDa (type I TGF-13
receptor, TI3R-I), and a 70 kDa (type II TGF-13 receptor, TI3R-II),
the cytoplasmic domaine have serine threonine kinase activity [15,
16]. In addition, a 200 to 400 kDa (type III TGF-/3 receptor,
T/3R-III) non-signaling proteoglycan has been described [15—21].
This receptor, also called betaglycan, is required for the presen-
tation of TGF-s to the TI3R-I/T/3R-II complex [16, 19—21].
Studies using deletion mutants have indicated that TI3R-I and
TpR-II co-operate to initiate a signal [15, 16]. TI3R-II binds the
higands and sequestors Tf3R-I into a complex for signaling [16].
Recent studies indicate that the induction of growth factors may
play a pathobiological role in experimental acute and chronic
rejection [22—33]. TGF-pl has been implicated as a critical
regulatory molecule in the cause of renal fibrosis and arterioscle-
rosis [12, 34]. However, it is not known whether other TGF-13
isoforms and their receptors contribute to the perturbations that
occur in the renal rejection. Therefore, in the present study, we
investigated the expression of all three mammalian TGF-/3 iso-
forms (TGF-/31, TGF-p2, TGF-f33) and their signaling receptors
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Table 1. Monoclonal and polyclonal antibodies used in
immunohistochemistry on paraffin-embedded material
Lymphohistiocytic
Cluster Antibody Source specificity
CD 45 LCA° DAKO Common lymphocyte
marker
CD 20 L 26° DAKO B cells, follicular
dendritic cells
CD 3 CD 3 DAKO T cells
0
-
MAC 387° DAKO Macrophages,
histiocytic cells
Monoclonal antibodies DAKO, Dakopatts, Copenhagen, Denmark
(T/3R-I, TI3R-II) in human chronic renal allograft rejection by
Northern blot analysis and immunohistochemical staining.
Methods
Patients
Kidney samples of 10 patients (6 female, 4 male; median age
52.7 years; range 45 to 63 years) with chronic renal rejection,
established according to clinical records and histopathological
analysis, were analyzed. Before these samples were used in our
analysis the clinical diagnosis was verified by histopathological
examination by two independent pathologists. Immediately after
surgical removal of the kidney, the cortex was separated from the
medulla in the operating room and a larger representative area of
the separated cortex was cut approximately in half and used for
both histological fixation and molecular analysis in order to
ensure comparison. Tissues destined for histological analysis were
fixed in Bouin solution for 12 to 24 hours, then dehydrated
through graded alcohol and subsequently embedded in paraffin.
For RNA extraction the tissues were snap frozen in liquid
nitrogen immediately upon surgical removal, and maintained at
—80°C until use. The median range of time between the trans-
plantation and the episode of chronic kidney rejection was 51
months (range 5 months to 9 years). Patients were all nondiabetic
adults. From the rejected group one patient was free of immuno-
suppressive drugs prior to renal explantation, three patients were
administered prednisolone and salicylic acid and three patients
had a combination of prednisolone and salicylic acid with immu-
nosuppressive agents such as azathioprine and cyclosporine. Nor-
mal renal tissues were obtained from six patients undergoing
surgery because of renal cell carcinoma and from two previously
healthy individual through an organ donor program (4 female, 4
male; median age 54.75 years; range 28 to 80 years). The
expression of TGF-131, TGF-J32, TGF-133, TI3R-I and TpR-II was
assessed by Northern blot analysis and immunostaining in all
specimens.
Immunohistochemical staining
Paraffin-embedded sections (2 to 4 im thick) were immuno-
stained for TGF-131, TGF-f32, TGF-133, TI3R-1, TI3R-Il and for
lymphocyte and macrophage cell markers (Table 1) using the
streptavidin-peroxidase/biotin technique (Kirkegaard & Perry
Laboratories, Inc., Gaithersburg, MD, USA). Tissue sections were
submerged for 15 minutes in TBS buffer (10 mivi Tris-HC1, 0.85%
NaC1, pH 7.4) containing 0.1% (vol/vol) Triton X-100 and washed
for five minutes in TBS solution, as previously reported [35, 36].
Endogenous peroxidase activity was quenched by incubating the
slides in methanol and in methanol/0.6% hydrogen peroxide,
followed by washing in methanol and TBS!0.1% BSA [35, 36j.
Following treatment with hyaluronidase (1 mg/mI in 100 mM
sodium acetate, 0.85% NaCI), the sections were blocked for 30
minutes at 37°C with 10% normal goat serum prior to overnight
incubation at 4°C with isoform specific polyclonal TGF-pl,
TGF-2 and TGF-f33 antibodies (2.5 jsg/ml) diluted in TBS
containing 5% normal goat serum and 0.1% BSA [35, 36]. Bound
antibody was detected with a biotinylated goat anti-rabbit IgG
secondary antibody and streptavidin-peroxidase complex (Kirke-
gaard & Perry Laboratories), followed by incubation with diami-
nobenzidine tetrahydroehloride (0.05%) as the substrate and
counterstained with Mayer's hematoxylin.
To ensure antibody specificity, control slides were either incu-
bated in the absence of primary antibody or with an irrelevant lgG
antibody. In both cases no immunostaining was detected. The
isoform specific antibodies to mature TGF-131, TGF-2 and
TGF-133 were produced in the laboratory of Leslie Gold, and their
preparation and characterization are described in detail by Pelton
et al [361. Briefly, the antibodies were raised in rabbits to synthetic
peptides corresponding to amino acid residues 4-19 of TGF-31
and TGF-132 and 8-29 of TGF-133. Each antiserum was purified by
ammonium sulfate precipitation followed by peptide affinity chro-
matography using the respective peptide immunogen. The anti-
sera were shown to be isoform-specific by Western blot analysis
using mature recombinant TGF-f31 and TGF-133 and porcine
native TGF-2, as illustrated [36]. No cross-reactivity among the
antisera was observed. All tissue sections that were compared
were treated at the same time using identical incubation times and
dilutions of all reagents including the antisera. Antibody activity
was previously shown to be absorbed with 33 Molar excess of each
peptide used as immunogen [36, 37]. Each antiserum absorbed
with peptide showed no immunoreactivity, proving antibody spec-
ificity. Antibodies against T/3R1 and Tf3RII were obtained from
Santa Cruz Laboratories, California. Denaturation of the tissue by
fixation in formalin exposes the epitopes so that immunoreactivity
is enhanced. We have observed that frozen sections require ten
times more antisera to achieve similar intensity of immunostain-
ing (unpublished observation). This is consistent with the fact that
ten times more antisera was required if native TGF-p was not
reduced prior to SDS-PAGE in Western blot analysis (unpub-
lished observation).
Both monoclonal and polyclonal antibodies to lymphocyte (CD
45) and macrophage cell markers were used as primary antibodies
as detailed in Table 1. The individual antisera of T-cells (CD 3),
B-cells (CD 20) and macrophages (MAC 387) showed no cross-
reactivity. No immunostaining was detected when the slides were
processed either in the absence of the primary antibody or in the
presence of affinity purified non-immune rabbit or mouse anti-
IgG.
Grading of the immunohistochemical staining was defined on
the basis of the percentage of morphological changes occurring
over an area of the cortex, and was quatified according to the
number of positively stained cells: 0, no staining; (+) < 10%; +
10 to 30%; ++ 30 to 50%; +++ > 50%.
Probe synthesis
The TGF-131 eDNA probe consisted of a 280 bp EcoRI/XbaI
fragment of human TGF-/31 eDNA [38, 39]. The TGF-/32 cRNA
probe consisted of a 600 bp HindIIl/PstI fragment of human
TGF-132 eDNA [38], corresponding to nucleotides 253 to 853 [38,
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39]. The TGF-/33 cRNA consisted of a 125 bpXbaIIBglII fragment
of human TGF-p3 cDNA [38], corresponding to nucleotides
917-1042 [38, 39]. TJ3R-I and Tf3R-II cRNA probes were gener-
ated from a 377 bp and a 476 bp BamHI fragment of human
TI3R-I and T/3R-II cDNA [10]. The 7S cDNA probe consisted of
a 190 bp fragment of the mouse 7S cytoplasmic cDNA which cross
hybridizes with human 7S RNA [9, 10, 40]. The antisense cRNA
probes used for Northern blot analysis were radiolabeled with
[a-32P] CTP (Du Pont, Boston, MA, USA). All the membranes
were also hybridized with 7S in order to assess equivalent RNA
loading [40—42]. [a-32P] dCTP (Du Pont) was incorporated into
TGF-/31 and 7S cDNA probes using a random primer labeling
system (Boehringer-Mannheiin, Germany) [43].
Northern blot analysis
Total RNA was extracted by the guanidine isothiocyanate
method [44], size-fractionated on 1.2% agarose/1.8 M formalde-
hyde gels, and stained with ethidium bromide for verification of
RNA integrity and loading equivalency [40, 45]. The RNA was
electro-transferred onto Nylon membranes (GeneScreen; Du
Pont) and cross-linked by UV irradiation [40, 45]. The blots were
then prehybridized, hybridized and washed under conditions
appropriate for antisense cRNA riboprobes (TGF-/32, TGF-/33,
T/3R-I, T/3R-II) or cDNA probes (TGF-/31, 7S), as previously
described [9, 10, 35].
For the antisense riboprobes the blots were prehybridized
overnight at 65°C in 50% formamide, 0.5% sodium dodecyl
sulfate (SDS), 5 x SSC, S x Denhardt's solution (1 X Den-
hardt's = 0.02% ficoll, 0.02% polyvinylpyrrolidone, and 0.02%
bovine serum albumin), 250 jig/mI salmon sperm DNA, and 50
mM Na2PO, pH 6.5. The blots were then hybridized for 18 hours
at 65°C in the presence of I x 106 cpm/ml of the labeled antisense
riboprobe, washed twice at 65°C in a solution containing I x
SSPE (150 m'vi NaCl, 10 mrvt NaH2PO4, and 1 mivi EDTA) and
0.5% SDS, and twice at 65°C in a solution containing 0.1 x SSPE
and 0.5% SDS [40, 45].
For TGF-/31 and 7S cDNA probes the blots were prehybridized
overnight at 42°C in a prehybridization buffer that contained 50%
formamide, 1% SDS, 0.75 M NaCI, 5 mivi EDTA, 5>< Denhardt's
solution, 100 jig/mI salmon sperm DNA, 10% Dextran sulfate and
50 mM Na2PO4, pH 7.4. The hybridization was carried out at 42°C
for 18 hours with the labeled cDNA probe (1 x 106 cpm/ml),
washed twice (23°C) in 2 >< SSC and three times at 55°C in 0.2 X
SSC and 2% SDS [40, 45].
Blots were then exposed at —80°C to Fuji X-ray film using
intensifying screens, and the intensity of the radiographic bands
was quantified by video densitometry (Biorad 620, USA), as
previously reported [40].
Statistical analysis
Results were expressed as mean or as median and range. For
statistical analysis the Wilcoxon-test was used [461. Significance
was defined as P < 0.05.
Results
Qironically rejected kidney shows increased and redistributed
immunoreactivily for TGF-13 isoforms compared to normals
TGF-/3 isoforms are secreted as latent molecules consisting of a
precursor, termed latent associated peptide (LAP), covalently
complexed to the mature potentially bioactive dimer (ie pro-TGF-
/3). Only the active mature dimer can bind to TGF-13 receptors.
Therefore, any antibodies produced to the mature amino acid
sequences of TGF-/3 isoforms will presumably detect the mature
molecules both, complexed to the LAP portion and separated
from the complex in its activated form (unless the epitopes on the
mature portion are masked by the LAP peptide). For this reason,
the antibodies will not be able to distinguish between the latent
and active molecules. Thus, the antisera detect potentially active
or activated TGF-/3 isoforms (that may or may not bind to TGF-/3
receptors).
Figure 1 shows the differences among the immunostaining
patterns obtained of TGF-f31, TGF-f32 and TGF-/33 in normal (A,
C, F) and rejected (B, D, F) renal samples. Figure 2 shows a
higher magnification to emphasize the major structures of immu-
nohistochemical localization of TGF-/31 in the rejected cortex.
Tables 3 and 4 summarize the pathological changes detected in
the rejected and the normal group. Grading was defined on the
basis of the percentage of morphological changes occurring over
an area of the cortex, and was quantified according to the number
of positively stained cells: 0, no staining; (+) < 10%; + 10 to
30%; ++ 30 to 50%; +++ > 50%.
Normal kidney samples exhibited intense immunoreactivity for
both TGF-131 (Fig. 1A) and TGF-/33 (Fig. 1E) in the proximal and
distal tubules in the renal cortex, whereas the interstitial space was
devoid of immunoreactivity. Only a few glomeruli showed mild
TGF-/31 immunostaining around the epithelial layer of the Bow-
man's capsule (Fig. 2 A, B). The endothelium and the mesangium
of the normal glomeruli, as well as the large vessels and peritu-
bular capillaries did not exhibit TGF-131 immunoreactivity (Fig.
1A; Fig. 2 A, B). TGF-/32 immunoreactivity was slight in most of
the normal tissues (Fig. 1C).
Rejected kidney samples exhibited a decrease in the intensity of
TGF-/31 (Figs. lB and Fig. 2 C, D) and TGF-133 (Fig. iF)
immunoreactivity in the tubules by comparison with the normal
specimens (Fig. 2 A, B, and Table 4). A minimal number of the
tubules were positively stained, most notably the proximal ones. In
contrast, immunoreactivity in the glomeruli for TGF-/31 (Fig. 1-B;
Fig. 2-C,D) and TGF-/33 (Fig. 1-F) was markedly increased in the
epithelial and intraglomerular cells in the chronically rejected
kidneys. The peritubular capillaries and the characteristically
thickened intimal layer of the cortical vessels in the rejected
kidney were also positively immunostained for TGF-131, TGF-132
and for TGF-J33 in contrast to the normal tissues (Fig. 1 B, D, F).
Moreover, strong immunoreactivity for TGF-/31 and TGF-133 was
detected among the infiltrating lymphocytes, macrophages and
other inflammatory cells of the grafted kidney (Table 3). TGF-f32
immunostaining in the rejected kidney showed less differentiated
changes compared to normal samples. The intensity of immuno-
staining was mild and more intense staining was only detected in
2 out of the 10 rejected specimens. As shown in Figure 3, T/3R1
and TJ3RII immunoreactivity exhibited the same pattern of dis-
tribution as TGF-/31 and TGF-/33 in the rejected renal tissue.
Figure 4 illustrates the immunostaining of the various immu-
nocells infiltrating the graft. Chronically rejected samples were
characterized by a strong infiltration of T-lymphocytes (CD 3) and
macrophages (MAC 387) localized diffusely throughout the whole
tissue (Fig. 4 C, E). In contrast, B-lymphocytes (CD 20) were
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Fig. 1. TGF-/3 immunostaining in normal (A, C, E) and rejected (B, D, F) renal tissues. The same area is examined in consecutive slides. Symbols are:
(black arrow) nonstaining arteries in normal renal tissue; (black triangle) intact glomeruli in normal cortex; (white arrowhead) positive staining in the
epithelial and mesangial part of the rejected glomeruli; (black arrowhead) positive staining in the intimal layer and endothelial cells of the sclerotic
arteries in rejected grafts. Original magnification is X200.
found focally, accumulating around and in the damaged glomeruli
but were not associating with the intact glomeruli of the rejected
specimens, as shown in Figure 4D.
TGF-f3 isoform and receptor mRNA levels are decreased in
rejected kidney specimens
Northern blot analysis of total renal RNA was performed to
determine the levels of TGF-f31, TGF-132, TGF-/33, Tf3R-I and
TI3R-II mRNA in both rejected and normal renal cortexes (Fig.
5). As shown in Figure 6, densitometric scanning of all the
rejected tissues compared to normal samples indicated an overall
decrease in mRNA for TGF-f31, TGF-/32, TGF-p3, T/3R-I and
TJ3R-II in the rejected specimens. Furthermore, this decrease
tended to vary directly with the general fibrosis in rejection. In the
rejected tissues there was a 1.41-, 1.95- and 2-fold decrease in
TGF-f31, TGF-p2 and TGF-p3 mRNA levels respectively, com-
pared to the corresponding levels in the normal controls (Fig. 6).
Tf3R-I and Tf3R-II mRNA levels were 1.3-fold and 3.61-fold
decreased in rejection. However, these differences were statisti-
cally significant only in the case of TGF-133 (P < 0.02) and TI3R-II
(P < 0.02) mRNA levels.
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Fig. 2. Significant characteristic localization of TGF-f31 in the normal kidney (A, B) compared to chronic allograft rejection (C, D) detected by
immunohistochemical analysis. A nonstaining intact glomeruli (A) and an intact artery in normal tissue (B). Symbols are: (black arrow) positive
glomerular epithelial staining; (white arrowhead) positive intraglomerular mesangial staining; (black arrowhead) positive staining in the intimal layer
of the arteries; (black triangle) positive tubular staining. Original magnification ><400.
Fig. 3. TI3RI (A, B) and T13RII (C, D)
immunostaining in normal (A, C) and rejected
(B, D) renal tissues. The same area is examined
in consecutive slides, black arrow: positive
tubular staining, white arrowhead: positive
glomerular epithelial staining. Original
magnification is x200.
a.
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Table 2. Role of growth factors after different organ transplantations
Transplanted tissue Growth factor Correlation with rejection-CAV Author, date, source, [Ref]
1. Cornea—human EGF In vitro pre-treated tissue prevents rejection Lass, 1994 Ophthalmology [24]
2. Langerhans islet—mouse TGF-13 Elevated. Prevention of rejection? Gill, 1991 Transplant Proc [25]
3. Langerhans islet—rat to mouse TGF-/3 In vitro pre-treated tissue prevents rejection Card, 1993 Transplantation [261
4. Liver—human bFGF Elevated. Chronic rejection identification? Bishop, 1992 Transplant Proc [27]
5. Aorta—rat PDGF, EGF, IGF-1 Elevated in CAV/chronic rejection Häyry, 1993 FASEB J [28]
6. Heart—rat TGF-131,2,3, LTBP Elevated. Responsible for rejection? Waltenberger, 1993 J Immunol [29]
7. Heart & kidney—rat PDGF-f3 Elevated. Cause of CAy? Higgy, 1991 Transplant Proc [30]
8. Heart—human TGF-/3, FGF Elevated. Cause of CAy? Zhao, 1993 Clin Exp Immunol [22]
Zhao, 1993 Transplant [231
9. Heart—human PDGF Elevated. Cause of CAy? Shaddy, 1992 J Heart Lung Trans [31]
10. Renal—rat EGF Decreased in chronic rejection. Stein, 1993 Transplant Proc [32]
11. Renal—human
12. Renal—human
LMW-GF
serum ultrafiltrate
TGF-l31
Decreased to 0 level in CRF or rejection,
back to normal in good renal function
Increased TGF-/31, PAl-i and fibronectin
in glomeruli
Jacob, 1993 Clin Nephrol [33]
Shihab, 1995 JAm Soc Nephrol [34]
Abbreviations are CRF, chronic renal failure; CAy, chronic arterial vasculopathy.
Table 3. Grading of the pathological changes and staining intensity of
the graft infiltrating immune cells in renal cortex in the rejected and
normal kidney specimens
Normal Rejected
Glomeruli 0 + +
Arteriosclerosis 0; (+) + +
Fibrosis 0 + +
Necrosis 0 +
Lymphocytes + + +
Macrophages (+) +++
Grading was defined on the basis of the percentage of morphological
changes occurring over an area of the cortex, and was quantified according
to the number of positively stained cells: 0, no staining; (+), <10%; +,
10-30%; ++, 30-50%; +++, > 50%.
Discussion
Characteristic pathological changes of chronic renal allograft
rejection include the presence of interstitial fibrosis, arterioscle-
rosis and necrosis, glomerular ischemic simplification and tubular
atrophy. TGF-/3 isoforms especially TGF-J31 has been implicated
as a critical regulatory molecule in the cause of fibrosis and
arteriosclerosis [11, 12]. The role for TGF-p in the fibrotic
response is due to its ability to stimulate the production of
proteins that compose the extracellular matrix, including fibronec-
tin, collagens and proteoglycans. Moreover, TGF-f3 stimulates the
production of protease inhibitors to prevent breakdown of the
deposited matrix components. The most significant studies indi-
cating a causative role for TGF-13 in an animal model of glomer-
ulonephritis were those of Border et al [12]. In these studies
neutralizing antibodies to TGF-f3 completely obviated the fibrotic
response in experimentally induced glomerulonephritis in rats
[12]. Similar pathological changes were observed in the glomeru-
lar epithelium and mesangium in glomerulonephritis and progres-
sive kidney fibrosis [47, 48]. The increased expression of TGF-131
and TGF-/33 in the vasculature most likely mediates the intimal
proliferation, which causes arteriosclerosis, thereby accelerating
the process of chronic renal allograft rejection.
An important function of TGF-s which may effect chronic
renal allograft rejection is their role in the regulation of the
immune response [6—81. TGF-f3s furthermore have immunosup-
pressive effects upon various target cells within the immune
system in vivo [49, 50], which would have an effect in preventing
Table 4. Staining intensity of TGF-13s and graft infiltrating cell markers
in renal cortex
Normal Rejected
TGF-j31
BC 0 ++
TUB ++ +
TGF-/32
BC 0 +
TUB + +
TGF-f33
BC 0 +++
TUB ++ +
Lymphocytes (CD 45) + +++
T cells (CD 3) (+); + ++
B cells (CD 20) 0; (+) +++
Macrophages (MAC-387) (+) +++
Abbreviations are: BC, Bowman's capsule; TUB, tubules; CD 45,
general lymphocyte marker; CD 3, T cell marker; CD 20, B cell marker;
MAC 387, macrophage marker. Grading was defined on the basis of the
percentage of morphological changes occurring over an area of the cortex,
and was quantified according to the number of positively stained cells: 0,
no staining; (+), <10%; +, 10—30%; ++, 30—50%; +++, > 50%.
rejection. For example a possible mechanism could be the sup-
pression of T-cell activation by antagonizing the function of IL-i
and IL-2 [2, 3]. TGF-f3s can also inhibit B-lymphocyte differenti-
ation and proliferation [8, 51]. However, TGF-f3s also demon-
strate other effects on immune cells, which would promote the
process of rejection such as chemotactic effects on monocytes and
macrophages [6—8].
Table 2 summarizes certain growth factors studied, and their
possible or putative function in both ameliorating or causing
rejection in the transplantation of various organs. Several studies
reported upregulation of TGF-p, EGF, FGF or PDGF both in
human and animal models of chronic rejection after cornea,
Langerhans islet, liver, aorta or heart transplantation [24—3 1].
Only three have studied kidney allograft rejection, and in contrast
to our studies, in chronic renal allograft rejection down-regulation
of epidermal growth factor (EGF) and other growth factors such
as IGF-I and IGF-II were found. Stein-Oakley et al reported
lower EGF levels in a rat model of chronic kidney rejection,
detected by Northern blot and immunohistochemical analysis
[321. In humans, Jacob et al measured decreased low molecular
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Fig. 4. Graft infiltrating immune cells in chronically rejected renal tissue.
Compared to the negative staining for graft infiltrating immune cells in
normal renal tissue (A) lymphocyte (CD 45) and T-cell (CD 3)
immunostaining detected diffusely infiltrating lymphocytes (B) and T-
cells (C) in chronic allograft rejection. B-lymphocytes (CD 20) were
found focally around the damaged glomeruli (D; black arrow), but not
accumulating around the intact ones (D; black arrowhead). MAC 387
antibody stained diffusely the infiltrating macrophages in samples of
chronic renal allograft rejection (E). Original magnification is x200.
weight growth factor levels (IGF-I, IGF-II) in serum ultrafiltrates
with bioassay technique [33]. Shihab et al found an increase in
TGF-131 mRNA and protein in glomeruli of chronicly rejected
human kidney allografts when needle bipsies were taken [34].
However, they did not examine the other TGF-j3 isoforms and
their receptors and the concomitant localization of immune cells
in kidney rejection in their studies.
The tendency for TGF-/3s and T/3Rs mRNA levels to be
decreased in the rejected kidneys was not statistically significant
with the exception of TGF-133 and TJ3R-II mRNA levels. This
decreased expression paralleled the general cell and tissue de-
struction associated with chronic renal rejection, and was most
likely due to the marked loss of tubular cells in the rejected
samples. In contrast, Shihab et al found increased TGF-pl mRNA
(and protein) in the tissue specimens of chronicly rejected kidney
allografts compared to normal. The difference between the two
studies may be due to the presence of less necrosis in their
samples which may have been derived from kidney with less
severe disease [34]. In our study, the increase in TGF-/31 and
TGF-133 immunoreactivity was limited to the less abundant gb-
meruli and vascular structures. Thus, there was a redistribution of
TGF-/31 and TGF-133 expression in the rejected kidney from the
tubular cells to the glomeruli. Since the glomerular epithelial and
mesangial cells are most likely responsible for the extracellular
matrix production in the kidney [47], our findings raise the
possibility that enhanced expression of TGF-/31 and TGF-133
within the gbomeruli contribute to the fibrosis in chronically
rejected renal allografts.
Immune cell staining (detected by markers) revealed the distri-
bution pattern of lymphocytes (CD 45), T-cells (CD 3) and
Rejected Normal
a a
— a —
:, 7
s a a t.i:t
1*• sip Fig. 5. Northern blot analysis of TGF-/31, TGF-/32, TGF-/33 and Tf3R-I and T3R-II mRNA in 6rejected and in 6 normal kidney samples. The
same samples were run in all blots in the same
order. 7S RNA was used to verity equal RNA
loading.
Fig. 6. Densitometric analysis. The ratio of
optical density between TGF-/31, TGF-/32,
TGF-/33, T/3R-I, TI3R-II and the corresponding
7S signals were calculated. Bars represent the
mean values: (E) rejected; () normal. *P <
0.02
macrophages (MAC-387) showed diffuse localization in the re-
jected kidney samples. Specific immunostaining for CD 20 de-
tected B-lymphocytes accumulating focally around the glomeruli
in the chronically rejected allografts, whereas in the normal
tissues there was no immunoreactivity for TGF-13s in the glomer-
ular structures, consistent with no evidence of B-cell infiltration.
Cell mediated immunity has been shown to be involved in host
versus graft reaction of tissue rejection. Therefore, it is interesting
that both TGF-/3, a potent immunosuppressive agent, and B-cells
co-localized to the glomeruli involved in apparent tissue destruc-
tion. This observation raises the possibility that TGF-131 and
TGF-133 may also participate in the regulation of B-cell mediated
immune responses involved in glomerular destruction. Further
studies are necessary to evaluate this possibility.
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